BRPI0918449A2 - compostos de anel espiro-tricíclico como moduladores de beta-secretas e métodos de uso - Google Patents

compostos de anel espiro-tricíclico como moduladores de beta-secretas e métodos de uso

Info

Publication number
BRPI0918449A2
BRPI0918449A2 BRPI0918449A BRPI0918449A BRPI0918449A2 BR PI0918449 A2 BRPI0918449 A2 BR PI0918449A2 BR PI0918449 A BRPI0918449 A BR PI0918449A BR PI0918449 A BRPI0918449 A BR PI0918449A BR PI0918449 A2 BRPI0918449 A2 BR PI0918449A2
Authority
BR
Brazil
Prior art keywords
spiro
secret
modulators
beta
methods
Prior art date
Application number
BRPI0918449A
Other languages
English (en)
Portuguese (pt)
Inventor
Kreiman Charles
C Yuan Chester
La Daniel
Huang Hongbing
Marx Isaac
B Human Jason
Weiss Matthew
Liu Qingyian
White Ryan
F Patel Vinod
Van Ma Vu
Qian Wenyuan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BRPI0918449A2 publication Critical patent/BRPI0918449A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BRPI0918449A 2008-09-11 2009-09-11 compostos de anel espiro-tricíclico como moduladores de beta-secretas e métodos de uso BRPI0918449A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9608208P 2008-09-11 2008-09-11
PCT/US2009/056748 WO2010030954A1 (en) 2008-09-11 2009-09-11 Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use

Publications (1)

Publication Number Publication Date
BRPI0918449A2 true BRPI0918449A2 (pt) 2019-09-24

Family

ID=41319591

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918449A BRPI0918449A2 (pt) 2008-09-11 2009-09-11 compostos de anel espiro-tricíclico como moduladores de beta-secretas e métodos de uso

Country Status (21)

Country Link
US (1) US8426447B2 (enExample)
EP (1) EP2328903B1 (enExample)
JP (1) JP5579720B2 (enExample)
KR (1) KR20110073511A (enExample)
CN (1) CN102209721A (enExample)
AU (1) AU2009291602B2 (enExample)
BR (1) BRPI0918449A2 (enExample)
CA (1) CA2736130C (enExample)
CL (1) CL2011000516A1 (enExample)
CO (1) CO6362014A2 (enExample)
CR (1) CR20110134A (enExample)
EA (1) EA201100461A1 (enExample)
ES (1) ES2459195T3 (enExample)
IL (1) IL211440A0 (enExample)
MA (1) MA32705B1 (enExample)
MX (1) MX2011002705A (enExample)
MY (1) MY148558A (enExample)
PE (1) PE20110805A1 (enExample)
TW (1) TWI385175B (enExample)
WO (1) WO2010030954A1 (enExample)
ZA (1) ZA201102674B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2010105179A2 (en) * 2009-03-13 2010-09-16 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
JP5828848B2 (ja) 2010-02-24 2015-12-09 ヴァイティー ファーマシューティカルズ，インコーポレイテッド ベータセクレターゼインヒビター
US8497264B2 (en) * 2010-03-15 2013-07-30 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
MX2012010658A (es) * 2010-03-15 2012-12-05 Amgen Inc Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa.
WO2011130741A1 (en) * 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
WO2012019056A1 (en) * 2010-08-05 2012-02-09 Amgen Inc. Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
MX2013002208A (es) 2010-08-23 2013-05-30 Amgen Inc Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
EP2644607A4 (en) * 2010-11-22 2014-05-28 Idemitsu Kosan Co OXYGENIC FUSIONED RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT THEREWITH
US20120157448A1 (en) * 2010-11-22 2012-06-21 Adam Cook Compounds for treating neurodegenerative diseases
WO2012071279A1 (en) * 2010-11-23 2012-05-31 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
WO2012112462A1 (en) 2011-02-15 2012-08-23 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2718287A1 (en) 2011-06-07 2014-04-16 F.Hoffmann-La Roche Ag [1,3]oxazines
RU2014111055A (ru) 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
WO2013044092A1 (en) * 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
ES2566373T3 (es) * 2011-10-10 2016-04-12 Astrazeneca Ab Inhibidores monofluoro beta-secretasa
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
EP2650284A1 (en) * 2012-04-10 2013-10-16 Merz Pharma GmbH & Co. KGaA Heterocyclic derivatives as metabotropic glutamate receptor modulators
SG11201407796YA (en) 2012-05-30 2014-12-30 Comentis Inc Chromane compounds
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US10548882B2 (en) 2012-06-21 2020-02-04 Astrazeneca Ab Camsylate salt
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
WO2014052398A1 (en) 2012-09-28 2014-04-03 Vitae Pharmaceuticals, Inc. Inhibitor of beta-secretase
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2016126726A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors
TW201629026A (zh) 2015-02-02 2016-08-16 佛瑪治療公司 作為ｈｄａｃ抑制劑的３－烷基雙環［４，５，０］異羥肟酸
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
DE102023106829A1 (de) 2023-03-19 2024-09-19 List Technology Ag Verfahren und Vorrichtung zur Behandlung eines Ausgangsproduktes

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683718A (en) * 1952-01-11 1954-07-13 Searle & Co Spiro-[xanthene-9, 4'-imidazolidine]-2, 5-dione
US3185696A (en) * 1959-03-12 1965-05-25 Jack M Tien 3', 6'-diaminofluoran derivatives of gamma-lactam
FR2576178B1 (fr) 1985-01-24 1987-04-17 Furodet Philippe Procede de fabrication pour un enfumoir a chargement par-dessous
DE3601492A1 (de) 1986-01-20 1987-07-23 Vacuumschmelze Gmbh Verfahren zur herstellung eines stabilisierten filament-supraleiters mit hohem anteil an stabilisierungsmaterial
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
SI9300303A (en) * 1993-06-08 1994-12-31 Krka Tovarna Zdravil Process for isolation of hypolipemic effective substance
JPH11507538A (ja) * 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
ES2318902T3 (es) * 1998-09-24 2009-05-01 PHARMACIA & UPJOHN COMPANY LLC Secretasa en la enfermedad del alzheimer.
MY138097A (en) 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
CA2410680A1 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
US7196163B2 (en) 2001-05-22 2007-03-27 Merk & Co., Inc. Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
CA2452039A1 (en) * 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
KR100713137B1 (ko) 2001-06-28 2007-05-02 동화약품공업주식회사 신규의 2,4-디플루오로벤즈아미드 유도체
MXPA04000328A (es) * 2001-07-10 2004-07-23 Pharmacia & Upjohn Comapny Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer.
JP2005504022A (ja) * 2001-07-10 2005-02-10 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病治療のためのジアミンジオール
US20030109559A1 (en) * 2001-07-11 2003-06-12 Andrea Gailunas N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds
CA2462851A1 (en) * 2001-10-04 2003-04-10 Elan Pharmaceuticals, Inc. Hydroxypropylamines
US20050027007A1 (en) 2001-10-05 2005-02-03 Roy Hom Allylamides useful in the treatment of alzheimer's disease
JP2005535559A (ja) * 2001-10-29 2005-11-24 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー アルツハイマー病を治療するためのヒドロキシ置換アミド
AR039555A1 (es) * 2001-11-08 2005-02-23 Upjohn Co Derivados n,n'-sustituidos de 1,3-diamino-2-hidroxipropano
TW200304374A (en) * 2001-11-30 2003-10-01 Smithkline Beecham Plc Novel compounds
WO2003050073A1 (en) * 2001-12-06 2003-06-19 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
AU2003206413A1 (en) * 2002-01-04 2003-07-24 Elan Pharmaceuticals, Inc. Substituted amino carboxamides for the treatment of alzheimer's disease
RS63204A (sr) * 2002-01-17 2006-10-27 Neurogen Corporation Supstituisani analozi hinazolin-4-ilamina kao modulatori kapsaicina
US7115652B2 (en) * 2002-06-17 2006-10-03 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
AU2003276047A1 (en) * 2002-06-17 2003-12-31 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
JP2005533811A (ja) 2002-06-20 2005-11-10 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ５−（１，３−オキサゾル−２−イル）安息香酸誘導体の調製方法
UY27967A1 (es) * 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
DE60329316D1 (de) * 2002-11-12 2009-10-29 Merck & Co Inc Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
GB0228410D0 (en) * 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
EP1583750B1 (en) * 2003-01-07 2013-02-27 Merck Sharp & Dohme Corp. Macrocyclic beta-secretase inhibitors for treatment of Alzheimer's disease
JP2006520371A (ja) * 2003-03-14 2006-09-07 メルク　シャープ　エンド　ドーム　リミテッド 軽症の認識損傷の治療方法及びアルツハイマー病の予防又は遅延方法
GB0305918D0 (en) * 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
CL2004000848A1 (es) * 2003-04-21 2005-01-28 Elan Pharmaceuticals Inc Pharm Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras
TW200512195A (en) * 2003-04-21 2005-04-01 Elan Pharm Inc Benzamide 2-hydroxy-3-diaminoalkanes
JP2007516207A (ja) * 2003-06-30 2007-06-21 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病の治療のためのＮ−アルキルフェニルカルボキサミドβ−セクレターゼ阻害剤
JP2007522088A (ja) * 2003-07-01 2007-08-09 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病の治療用フェニルカルボン酸ベータセクレターゼ阻害剤
US7700603B2 (en) * 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) * 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2548388A1 (en) 2003-12-15 2005-06-30 Schering Corporation Heterocyclic aspartyl protease inhibitors
GB0402143D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
JP2007530696A (ja) 2004-03-30 2007-11-01 メルク　エンド　カムパニー　インコーポレーテッド アスパラギン酸プロテアーゼ阻害剤として有用な２−アミノチアゾール化合物
CA2579724A1 (en) * 2004-06-16 2006-01-26 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
US20090221579A1 (en) 2004-10-15 2009-09-03 Jeffrey Scott Albert Substituted Amino-Compounds and Uses Thereof
CN101103034A (zh) 2005-01-14 2008-01-09 惠氏公司 抑制β-分泌酶的氨基-咪唑酮
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
EP1896406A2 (en) 2005-06-14 2008-03-12 Shering Corporation The preparation and use of compounds as protease inhibitors
US8722708B2 (en) 2005-06-14 2014-05-13 Merck Sharp & Dohme Inc. Substituted isoindolines as aspartyl protease inhibitors
CA2612491A1 (en) * 2005-06-16 2006-12-28 Janssen Pharmaceutica N.V. Tricyclic opioid modulators
TW200738683A (en) * 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
WO2007009014A2 (en) * 2005-07-13 2007-01-18 Raviv Laor Personal topical disinfectant device
CA2615656A1 (en) 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
TW200730523A (en) * 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
RU2008106936A (ru) * 2005-09-26 2009-11-10 Вайет (Us) Соединения амино-5-[4-(дифторметокси)фенил]-5-фенилимидазолона для ингибирования бета-секретазы
ES2537898T3 (es) * 2005-10-25 2015-06-15 Shionogi & Co., Ltd. Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1
WO2007100536A1 (en) * 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
JP2009532464A (ja) 2006-04-05 2009-09-10 アストラゼネカ・アクチエボラーグ ２−アミノピリミジン−４−オン及びＡβ−関連の病理を治療又は予防するためのその使用
TW200808751A (en) 2006-04-13 2008-02-16 Astrazeneca Ab New compounds
CA2653650A1 (en) * 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
US8293759B2 (en) 2006-10-30 2012-10-23 Merck, Sharp & Dohme, Corp. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
TW200831484A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
TW200831091A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
CA2675221C (en) 2007-02-02 2016-02-23 F. Hoffmann-La Roche Ag Novel 2-aminooxazolines as taar1 ligands
PE20090617A1 (es) 2007-03-23 2009-05-08 Wyeth Corp Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
EP2151435A4 (en) * 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
AU2008245082B8 (en) * 2007-04-24 2012-09-13 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
TW200902503A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
BRPI0906962B8 (pt) * 2008-01-18 2021-05-25 Eisai R&D Man Co Ltd composto de aminodiidrotiazina fundido
CN101952260B (zh) * 2008-02-18 2013-02-13 弗·哈夫曼-拉罗切有限公司 4,5-二氢-*唑-2-基胺衍生物
AU2009239536C1 (en) 2008-04-22 2012-12-13 Merck Sharp & Dohme Corp. Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
ES2556633T3 (es) 2008-07-24 2016-01-19 F. Hoffmann-La Roche Ag Derivados de 4,5-dihidro-oxazol-2-ilo
AU2009277485B2 (en) * 2008-07-28 2013-05-02 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives

Also Published As

Publication number Publication date
JP2012502112A (ja) 2012-01-26
MY148558A (en) 2013-04-30
CO6362014A2 (es) 2012-01-20
JP5579720B2 (ja) 2014-08-27
CR20110134A (es) 2011-08-04
CN102209721A (zh) 2011-10-05
ZA201102674B (en) 2011-12-28
IL211440A0 (en) 2011-05-31
US20100087429A1 (en) 2010-04-08
EP2328903A1 (en) 2011-06-08
TWI385175B (zh) 2013-02-11
PE20110805A1 (es) 2011-11-09
ES2459195T3 (es) 2014-05-08
MX2011002705A (es) 2011-09-09
WO2010030954A1 (en) 2010-03-18
CA2736130C (en) 2014-01-14
CA2736130A1 (en) 2010-03-18
KR20110073511A (ko) 2011-06-29
TW201022280A (en) 2010-06-16
AU2009291602B2 (en) 2013-02-14
EA201100461A1 (ru) 2011-10-31
EP2328903B1 (en) 2014-03-05
MA32705B1 (fr) 2011-10-02
CL2011000516A1 (es) 2011-08-26
US8426447B2 (en) 2013-04-23
AU2009291602A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
BRPI0921992A2 (pt) moduladores tgr5 e métodos de uso destes
BR112013014321A2 (pt) moduladores inovadores e métodos de uso
PT2585437E (pt) Compostos de tioacetato, composições e métodos de uso
BRPI0808684A2 (pt) moduladores de tgr5 e métodos de uso destes
BR112012018329A2 (pt) agentes de coloração e métodos de uso destes
BRPI0916735A2 (pt) moduladores de tgr5 e métodos de uso do mesmo
BRPI0913117A2 (pt) imidazopiridina e análogos relacionados como moduladores de sirtuína
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
CR20130168A (es) Moduladores de receptores de estrògenos y usos de los mismos
BR112012022746A2 (pt) uso de amissulprida como anti-emético
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
BRPI1012333A2 (pt) atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
ZA201102674B (en) Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
BRPI0910862A2 (pt) anel de pistão
BRPI1010774A2 (pt) método de uso de particulados.
BRPI1010197A2 (pt) métodos e compostos de pirazolopirimidina jak
PT2424372T (pt) Composições antimicrobianas e métodos de uso relacionados
CO6862157A2 (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimida y su uso como moduladores de receptoresde c5a
BRPI1010668A2 (pt) sensor ótico de método de uso
PT2376533T (pt) Formulação de anticorpos
BRPI1014544A2 (pt) anticorpors anti-il-17f e metodos de uso dos mesmos
BR112013016030A2 (pt) compostos e seu uso como inibidores de bace
EP2488206A4 (en) Porphyrin-NANOVESIKEL
BRPI0913086A2 (pt) Composições antimicrobianas e métodos de uso
BRPI1005670A8 (pt) composições adjuvantes e processos de uso.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.